CombiGene AB (publ): Nominating committee

Regulatory news 2021 2021   2020   2019   2018   2017   2016   2015   The nominating committee has been constituted in accordance with the resolution adopted by the annual general meeting (“AGM”) 2021 The AGM 2021 resolved that a nominating committee should be...

read more

Record date for reverse share split in CombiGene

Regulatory news 2021 2021   2020   2019   2018   2017   2016   2015 The Board of Directors of CombiGene AB (publ) ("CombiGene") has resolved that the record date for the reverse share split shall be 8 June. Through the reverse share split, twenty (20) existing shares...

read more

Bulletin from the annual general meeting of CombiGene AB (publ)

Regulatory news 2021 2021   2020   2019   2018   2017   2016   2015 The following resolutions were passed at the annual general meeting (the “AGM”) of CombiGene AB (publ) (“CombiGene”) on 25 May 2021. Adoption of income statement and balance sheet and discharge from...

read more

Notice of annual general meeting in CombiGene

Regulatory news 2021 2021   2020   2019   2018   2017   2016   2015 NOTE: This is an unofficial translation of the original Swedish notice. In case of discrepancies, the Swedish version shall prevail. The shareholders of CombiGene AB (publ) are hereby summoned to...

read more

CombiGene announces outcome in rights issue

Regulatory news 2021 2021   2020   2019   2018   2017   2016   2015 The information in this press release is not intended for publication, public release or distribution, directly or indirectly, in or into the USA, Canada, Japan, Australia, Hong Kong, New Zealand,...

read more

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.

The Company has an exclusive collaboration and licensing agreement for the CG01 project with Spark Therapeutics.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99



CombiGene AB, Agavägen 52A, SE-181 55 Lidingö


Linked In     Twitter      Facebook